Ocular Surface Disease Index
- Introduced by
- Schiffman RM, Christianson MD et al.
- Year
- 2000
- Type
- Self-report
- Family
- dry eye / ocular surface disease
What does it do?
The OSDI is a 12-item symptom questionnaire designed to screen for and grade the severity of dry eye disease and other ocular surface disorders.
Developed by Schiffman, Christianson, and colleagues (2000), it quantifies patient-reported ocular irritation and visual function limitations across frequency and impact domains. The OSDI is the most widely used screening tool for dry eye in clinical practice, clinical trials, and epidemiological studies worldwide.
The intuition behind the method
Dry eye disease (DED) is prevalent, often under-recognized, and causes progressive ocular surface inflammation. Patients experience intermittent burning, grittiness, tearing (paradoxical), and visual blur—symptoms that worsen with screen time, low humidity, and reduced blinking. Objective tests (Schirmer, tear osmolality, meibography, in vivo confocal microscopy) are heterogeneous and often poorly correlate with symptoms; patient-reported symptoms drive treatment decisions more than diagnostics. The OSDI captures symptom frequency and impact on function (reading, computer work, driving), enabling symptom-based DED grading and monitoring treatment response. A patient may have normal Schirmer test but high OSDI (suspected evaporative DED or neuropathic pain); conversely, low Schirmer with low OSDI (subclinical aqueous deficiency). Both require management, but symptom severity guides intensity.
History
Developed by Schiffman, Christianson, Jacobsen, and colleagues at RPS Pharma and SUNY College of Optometry (2000, published Arch Ophthalmol). Created in response to the lack of standardized symptom-based dry eye assessment and to facilitate clinical trial design for DED therapeutics. Rapidly adopted by ophthalmologists and optometrists; became the recommended screening tool in major dry eye guidelines (DEWS, TFOS-DEWS). Multiple-language translations and demographic validations followed. FDA has incorporated OSDI into regulatory guidance for DED drug approval. Remains the most cited ocular surface symptom measure in the literature.
When to use it
Recommended as a screening tool at every eye examination for patients with symptoms suggestive of dry eye (irritation, blur, foreign body sensation) or risk factors (age >50, female, contact lens wear, screen use, systemic disease, medication). Repeat OSDI at 4–6 week post-intervention to assess treatment response. Essential in clinical trials of DED therapeutics. Use alongside objective tests (Schirmer, staining, osmolality) for comprehensive DED assessment, but do not rely on objective tests alone; symptom-based scoring (OSDI) takes priority in shared decision-making.
Limitations and considerations
- Symptom-only measure; does not capture objective signs (tear volume, osmolality, meibomian gland atrophy, ocular surface inflammation). A patient with low OSDI but objective evidence of DED (positive vital dye staining, high osmolality) requires clinical judgment regarding treatment.
- Moderate symptom-sign correlation: approximately 40–50% of patients with clinical DED have an OSDI score in the normal range (0–12), and vice versa (subclinical high OSDI)
- Does not distinguish cause of dry eye: OSDI is high in both aqueous-deficient and evaporative DED; additional testing required to guide targeted therapy
- Environmental and temporal influence: OSDI scores vary by season, climate, humidity, and time of day; baseline variability may reduce sensitivity to small therapeutic changes
- Limited discriminant ability in mild cases: overlap in OSDI scores between normal and mild DED (12–13 boundary) requires clinical context
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Highly practical: 12 items, 2–3 minute administration, no equipment required; feasible in any clinic or research setting
- Symptom-focused and functionally relevant: items address real patient concerns (reading, screen work, driving, environmental triggers), not abstract constructs
- Validated extensively: excellent internal consistency (Cronbach α 0.84–0.90), test-retest reliability (ICC >0.80), and discriminant validity (DED vs. non-DED populations)
- Responsive to treatment: OSDI improves with artificial tears, cyclosporine, warm compress, lid massage, omega-3, topical NSAIDs, and newer agents (lifitegrast, tyrosine kinase inhibitors); effect sizes large (Cohen d often >0.8)
- Internationally adopted: translated to 40+ languages, used in epidemiological studies, national surveys, and global DED registries; normative data widely available
How it works
How it works
12 items: 3 about ocular symptoms (dryness, grittiness, painful irritation), 4 about vision-related function (reading, screen work, driving, watching TV), 3 about environmental triggers (wind, low humidity, air conditioning), and 2 about temporal triggers (morning, evening). Respondents rate frequency of each symptom on a 5-point Likert scale (0 = never, 1 = sometimes, 2 = half the time, 3 = most of the time, 4 = all of the time). Administration is 2–3 minutes. Suitable for adults and older children (age 6+) with suspected or known ocular surface disease. Self-report or interview-administered. Can be paper, electronic, or web-based.
Each item is scored 0–4. The OSDI formula: (sum of all answered items × 100) / (number of items answered × 4). This normalizes for missing responses, yielding a 0–100 scale regardless of which items are omitted. Scores are converted to severity grades: 0–12 = normal, 13–22 = mild DED, 23–32 = moderate DED, >32 = severe DED. A 4-point change is considered a meaningful difference (MCID ~4 on 0–100 scale).
0–12: Normal ocular surface; no DED. 13–22: Mild DED; symptoms present but not severe; may benefit from conservative management (artificial tears, lid hygiene, environmental modification). 23–32: Moderate DED; significant symptoms and functional impact; topical or systemic therapy often warranted. >32: Severe DED; substantial symptom burden and visual dysfunction; requires intensive management (cyclosporine, lifitegrast, punctal occlusion, lid procedures, systemic therapy). OSDI scores correlate moderately with Schirmer test and tear osmolality (r ~0.3–0.5) but poorly with meibography or imaging—symptom-based assessment is primary. Longitudinal OSDI tracking (baseline, 4–12 weeks post-treatment) documents therapeutic response; improvement of ≥4 points is clinically meaningful.
DED case-finding in primary eye care: OSDI >12 prompts further diagnostic evaluation (Schirmer, ocular staining, osmolality) Severity grading and treatment selection: OSDI guides intensity of intervention (drops vs. topical/systemic therapy vs. in-office procedures) Monitoring treatment response: OSDI reduction after artificial tears, cyclosporine, omega-3, meibomian gland expression, or IPL validates efficacy Clinical trials and outcome research: OSDI is a primary endpoint in DED trials comparing novel therapies; FDA guidance endorses OSDI as a symptom anchor
Common pitfalls
- Over-treating based on OSDI alone: a patient with OSDI >32 but minimal objective signs and excellent quality of life may not benefit from intensive therapy; shared decision-making essential
- Under-treating objective DED with low OSDI: a patient with >3 clock hours of vital dye staining but OSDI <13 still has DED and may benefit from intervention
- Interpreting single OSDI snapshot without longitudinal context: a high score at one visit may reflect acute exacerbation (environmental, contact lens overwear, systemic disease flare), not baseline disease
- Forgetting to account for missing items in scoring: if a patient skips items (e.g., 'I don't drive'), the formula must normalize for answered items only—raw sum divided by total items × 25 gives incorrect 0–100 conversion if items omitted
Frequently asked questions
What OSDI score indicates dry eye disease, and what is the clinical cutoff?
OSDI >12 suggests possible DED; OSDI >23 indicates moderate DED. However, no single cutoff is diagnostic; clinical context is essential. A patient with OSDI 20 and substantial vital dye staining has DED warranting treatment. Conversely, a patient with OSDI 30 but no objective signs and normal quality of life may be managed conservatively. Always combine OSDI with objective tests and patient goals.
How much improvement in OSDI indicates treatment efficacy?
A reduction of 4 points is considered clinically meaningful (MCID). Typical improvements with effective therapy (artificial tears, cyclosporine): 5–15 point reduction over 4–12 weeks. Greater reductions (>15 points) are seen with intensive interventions (cyclosporine + punctal occlusion, meibomian gland procedures, systemic therapy).
Can OSDI be used to diagnose the type of dry eye (aqueous-deficient vs. evaporative)?
No. OSDI measures symptom severity, not etiology. Additional tests (Schirmer, meibography, tear osmolality, OCT of tear meniscus) are required to differentiate aqueous-deficient from evaporative DED. OSDI guides symptom management but not disease-specific mechanism.
Is OSDI suitable for children or contact lens wearers?
OSDI has been validated in children (age 6+) and adolescents, though most data come from adults. Contact lens wearers often have elevated OSDI due to lens-related irritation; OSDI can track improvement after lens refitting or removal. However, contact lens material and wearing time influence OSDI more than underlying DED in some patients; clinical judgment advised.
Related methods
Sources
Schiffman, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D., & Reis, B. L. (2000). Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol, 118(5), 615-621.
Open DOI referenceCopied.Begley, C. G., Chalmers, R. L., Abetz, L., & Vensel, B. (2003). The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci, 44(10), 4753-4761.
Open DOI referenceCopied.